

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 April 2018 (12.04.2018)



(10) International Publication Number
WO 2018/068021 A1

(51) International Patent Classification:

C07J 17/00 (2006.01) C07J 43/00 (2006.01)
C07J 41/00 (2006.01) C07J 51/00 (2006.01)

(21) International Application Number:

PCT/US2017/055660

(22) International Filing Date:

06 October 2017 (06.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/405,801 07 October 2016 (07.10.2016) US
62/526,331 28 June 2017 (28.06.2017) US

(71) Applicant: **ORIC PHARMACEUTICALS, INC.**
[US/US]; 240 E. Grand Avenue, 2nd Floor, South San Francisco, California 94080 (US).

(72) Inventors: **SUN, Daqing**; 804 Cortez Lane, Foster City, California 94404 (US). **MCGEE, Lawrence R.**; 39 Big Sur Way, Pacifica, California 94044 (US). **DU, Xiaohui**; 2735 Wemberly Drive, Belmont, California 94002 (US). **ZHU, Liusheng**; 752 Orion Lane, Foster City, California 94404 (US). **YAN, Xuele**; 1120 Nimitz Lane, Foster City, California 94404 (US). **REW, Yosup**; 828 Juno Lane, Foster City, California 94404 (US). **EKSTEROWICZ, John**; 1845 Church Street, San Francisco, California 94131 (US). **MEDINA, Julio C.**; 2879 Roland Ave, San Carlos, California 94070 (US). **FANTIN, Valeria R.**; 3133 Frontera Way, Apt 217, Burlingame, California 94010 (US). **ZHOU, Haiying**; 280 San Felipe Ave, Apt 3, San Bruno, California 94066 (US). **BALBAS, Minna Delarae**; 615 Monterey Blvd, Apt 2, San Francisco, California 94127 (US).

(74) Agent: **SMITH, Deborah M.**; WILSON SONSINI GOODRICH & ROSAIT, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF GLUCOCORTICOID RECEPTOR

(57) Abstract: The present invention relates generally to compositions and methods for treating cancer and hypercortisolism. Provided herein are substituted steroidal derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of glucocorticoid receptors. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.

WO 2018/068021 A1